-
Groundbreaking Studies to Be Conducted on the Effectiveness of Short and Long-term COVID-19 Therapies Inhibiting the Progression of SARS-CoV-2
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Statera Biopharma, Inc. (NASDAQ: STAB) recently announced that it has officially received Institutional Review Board (IRB) approval to conduct a Phase 1 pilot study at Loma Linda University Health to evaluate STAT-205 as a treatment in the mitigation of SARS-CoV-2 progression. STAT-205 is a breakthrough immuno-modulator designed to decrease elevated inflammatory responses that are associated with viral infections and inhibit viral replication in human lung cells. Its efficacy was successfully demonstrated during preclinical in vitro studies, where STAT-205 was able to inhibit the replication of…
You May Also Like
What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?
Research Shows that Animals, too, Need a Good Night’s Sleep
Biotricity Continues to Transform the Way We Do Health: Medtech Launches New Biokit Solution, Aims at Personal Health Monitoring
-
What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Statera Biopharma, Inc. (NASDAQ: STAB) — the company formerly known as Cytocom (NASDAQ: CBLI) — recently uplisted to the Nasdaq in lieu of earlier acquisitions involving Cleveland BioLabs and ImQuest Life Sciences, Inc. Last week, the company provided an update on its integration of ImQuest and its plans going forward. According to Statera, preclinical testing is underway in the screening of second-generation immune therapies using the ImQuest platform for the rapid and accurate assessment of various diseases and how the overall makeup and composition of these diseases interact. The company will look more closely…
